What is behind Moderna stock's recent gain in value today

Traders Union
All News
Financial News
Moderna rises 2.42% today to $48.17

Highlights

Moderna initiated early-stage research into an mRNA-based hantavirus vaccine with U.S. and Korean partners as part of its pipeline expansion.
The FDA will review Moderna's mRNA flu vaccine on June 18, potentially impacting future regulatory prospects after prior setbacks.
Moderna trades near short-term resistance amid mixed momentum signals, with a projected five-day range of $45.08 to $50.23 and an 80% probability of upward movement.

Early vaccine pipeline and leadership shift drive mixed sentiment

Moderna has announced early-stage research into an mRNA-based hantavirus vaccine in partnership with the U.S. Army Medical Research Institute of Infectious Diseases and Korea University under its mRNA Access Program. The company’s mRNA flu vaccine, previously not accepted by the FDA, is scheduled for discussion at an advisory committee on June 18. Additionally, Moderna appointed Piyali Mukherjee as Head of Medical Affairs for Europe and the Middle East.

Anton Kharitonov, expert at Traders Union, believes Moderna's short- and medium-term trends show continued weakness despite the recent price uptick. He notes that momentum signals are mixed, with a daily MACD sell, neutral ADX, and no strong positioning from RSI or CCI. News of early-stage vaccine research and recent management changes are not enough to offset negative sentiment tied to FDA hesitancy. Kharitonov highlights that the risk of a breakdown below $45.08 is significant if resistance at $50.23 holds. He remarks, "I remain cautious and see no clear reason for sustainable upside until momentum improves or regulatory concerns ease."

Viktoras Karapetjanc, expert at Traders Union, sees ongoing research initiatives and regional leadership appointments as bullish drivers for Moderna. He notes the long-term price structure remains intact, given strong support above the 200-day average. Karapetjanc expects the upcoming advisory committee on Moderna’s mRNA flu vaccine to spark positive repricing if outcomes turn favorable. He states, "Further growth is likely as the market looks for validation of Moderna's mRNA platform in new indications and geographies."

Conflicting technical signals as buyers test resistance zone

The nearest dynamic resistance for MRNA is the Ichimoku Kijun level at $51.59, while the 200-day moving average at $37.15 provides key long-term support. Momentum indicators are mixed: MACD signals a daily sell, ADX remains neutral, and both the RSI and CCI show neither overbought nor oversold conditions. Stochastic RSI is also close to neutral. Bull/Bear Power (BBP) is positive at 0.27 as intraday buyers dominate, though the BBP’s oversold reading hints at recent downside exhaustion. The stock saw a $1.14 gain since the previous close, trading in the middle of its daily range with intraday volatility at 4.38%. Price action has a firm upward tone after the open, but overall signals point to an indecisive backdrop due to conflicting momentum and oscillator readings.

Earlier, analysts noted that while Moderna faced sustained bearish momentum in the short and medium term, its constructive long-term outlook and positive pipeline updates offered potential for sentiment improvement. With the latest price action reflecting a shift toward indecision amid elevated volatility and major regulatory milestones approaching, traders should closely monitor for a breakout above $50.23 as confirmation of renewed bullish momentum.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.